| Editor’s Note: Happy Halloween! |
|
January 9-10, 2024 | San Francisco, CA January 16-18, 2024 | Virtual Driving the Future of Companion Diagnostics: Technology, Translational Medicine, & Commercialization in the Next Decade. Register today and Save $450! 
|
|
Today’s Big NewsOct 31, 2023 |
| By Nick Paul Taylor Amgen’s Teneobio misadventure has taken a $650 million BiTE out of its earnings. The Big Biotech took the hit after stopping a phase 1 trial of the PSMA bispecific it picked up in the $900 million acquisition of Teneobio two years ago. |
|
|
|
By Max Bayer Beam Therapeutics is selling off opt-in rights to Verve's cardio work to Lilly for up to $600 million. The three-way deal has been worked on in parallel with Beam's larger recently announced restructuring, CEO John Evans said in an interview. |
By Max Bayer,Gabrielle Masson More than 20 biotechs entered the biotech graveyard this year, spurred by a difficult financing environment. There were more than three times as many companies that closed or wound down in 2023 compared to 2022. |
Sponsored by Medidata The clinical trial landscape has seen a seismic shift in recent years, spurred by technology-driven data collection. Yet there are some opportunities… |
|
Convert more DNA into sequenceable library for enhanced sensitivity — particularly with cfDNA samples and ctDNA detection. Prepare highly complex libraries in under 2 hours from as little as 500 pg. Explore the data. .png)
|
|
By Max Bayer Amgen is wary of placing too much confidence in early obesity candidates, cautioning investors that it'll have a better sense of how much to invest in an oral option once a phase 1 trial reads out next year. |
By Gabrielle Masson Pfizer’s new cost-saving agenda will see five pipeline programs in oncology, rare disease and immunology packed off to the graveyard. |
By Nick Paul Taylor Pfizer has capped off a landmark six weeks for the push to apply mRNA to influenza. Following a flurry of positive updates from Pfizer and chief mRNA rival Moderna, the Big Pharma has revealed a phase 3 trial of its mRNA flu candidate met both primary endpoints—but a secondary endpoint miss raises questions. |
By Annalee Armstrong Arrowhead Pharmaceuticals finally knows the future of its hepatitis B med: Johnson & Johnson has offloaded the rights to GSK. |
By Annalee Armstrong Daiichi-Sankyo, coming off a successful trip to Madrid that included a mega deal and a data drop to set the record straight on its next ADC candidate’s safety, is setting up for a lucrative few years. |
By Gabrielle Masson Blue Owl Capital is expanding its nest, inking a deal to acquire funds managed by Cowen Healthcare Investments (CHI), an acquisition that will add about $1 billion in assets across several funds with a specific focus on mid-to-late-stage equity investments in biopharmas and healthcare companies. |
By Annalee Armstrong 4D Molecular Therapeutics has offered to add an immunosuppressive regimen during administration of a Fabry disease gene therapy in order to continue with human testing and lift an FDA clinical hold placed earlier this year. |
By Gabrielle Masson With a new CEO in charge, Blue Water is reprioritizing its pipeline, dropping six-FDA approved drugs and a wide-ranging vaccine portfolio. |
By Helen Floersh New data from mouse and rat studies show that MeiraGTx’s ALS gene therapy repairs a key cell-killing process that’s common in both genetic and sporadic forms of the disease. |
By Helen Floersh Prime Medicine’s prime editors have corrected a gene mutation that causes a rare liver disease in primates, a step toward taking the tech to humans. |
By Eric Sagonowsky After Sarepta overcame several regulatory hurdles to finally win FDA approval for its DMD gene therapy Elevidys, the company now faces the prospect of more FDA scrutiny because a pivotal study on the drug has failed on the primary endpoint. |
By Conor Hale Olympus has told healthcare providers to stop using its insufflation hardware for laparoscopic surgery until further notice, while it examines reports of over-inflation. |
By Kevin Dunleavy For 50 million euros plus potential milestones of 120 million euros, Galapagos agreed to transfer its Jyseleca marketing authorizations and support staff to Alfasigma. Galapagos will cut another 100 jobs as part of its streamlining efforts. |
By Heather Landi Cleveland Clinic plans to launch a drone delivery service to bring certain medications directly to patients’ homes, starting in 2025. |
Fierce podcasts Don’t miss an episode |
| In this episode of “The Top Line,” we delve into the FDA's controversial approval of Aduhelm, a drug for Alzheimer's disease, despite an independent advisory committee's resounding rejection. The decision has sparked questions about potential bias within the regulatory body. |
|
|---|
|
|
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| Edison Ballroom, New York City |
|
|
| |
|
